Skip to content

Clinical Study of Hereditary Osteopetrosis

Clinical Study of Hereditary Osteopetrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074243
Enrollment
Unknown
Registered
2023-08-02
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary Osteopetrosis

Interventions

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 99 Years

Inclusion criteria

Inclusion criteria: (1) Osteopetrosis with clear clinical diagnosis (2) We have completed gene testing and confirmed the presence of TCIRG1, CLCN7, CA II, SNX10, TNFSF11, PLEKHM1, SLC29A3, and NEMO mutations (homozygous or compound heterozygous mutations, among which CLCN7 and PLEKHM1 can also be heterozygous mutations). (3) Volunteer to participate in this study

Exclusion criteria

Exclusion criteria: (1) High bone mass syndrome caused by other reasons, such as osteoarthritis, progressive diaphyseal dysplasia, melorheostosis, Paget bone disease, Erdheim Chester disease, etc (2) Poor compliance, unable to follow up regularly (3) Not willing to participate in this study

Design outcomes

Secondary

MeasureTime frame
hypercalcemia;veno-occlusive disease, VOD;graft versus host disease, GVHD;

Primary

MeasureTime frame
3-year survival rate;

Countries

China

Contacts

Public ContactChun Wang

Shanghai Sixth People's Hospital

wangchun66@sjtu.edu.cn+86 153 0169 0670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026